Acasti Pharma  logo
Acasti Pharma ACST
report update icon

Quarterly report 2027-Q2
added 11-12-2026

Acasti Pharma EBITDA | ACST

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Acasti Pharma

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
-11.1 M -16.7 M -12.8 M -52 M -15.6 M -16.3 M - -31 M -14 M - -5.33 M -8.04 M -8.11 M -6.17 M -5.88 M -2.42 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
-2.42 M -52 M -14.7 M

Quarterly EBITDA Acasti Pharma

2027-Q2 2027-Q1 2026-Q4 2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
-2.29 M -15.9 M -3.01 M -2.45 M -2.53 M -3.09 M -3.18 M -3.7 M -4.83 M - -3.26 M -3.04 M -2.08 M -4.96 M -3.04 M - -4.45 M -4.45 M -1.62 M -4.24 M -5.17 M -4.56 M -4.45 M -4.47 M -3.57 M -3.14 M -54 K -1.82 M -7.98 M -4.04 M -6.04 M -6.18 M -7.92 M 384 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
384 K -15.9 M -4.1 M

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer EBITDA Price % 24h Market Cap Country
Annexon Annexon
ANNX
-214 M $ 3.11 -8.94 % $ 482 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
22 K - -45.71 % $ 1.2 M canadaCanada
Galapagos NV Galapagos NV
GLPG
351 M - - $ 1.83 B belgiumBelgium
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
-417 K - -4.36 % $ 27 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
-3.08 M - -52.27 % $ 4.45 M usaUSA
Galmed Pharmaceuticals Ltd. Galmed Pharmaceuticals Ltd.
GLMD
83 K $ 4.63 21.05 % $ 20 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
228 K $ 6.78 0.89 % $ 296 M usaUSA
Leap Therapeutics Leap Therapeutics
LPTX
-41.1 M - 368.57 % $ 41.9 M usaUSA
Lumos Pharma Lumos Pharma
LUMO
-36.6 M - - $ 35.3 M usaUSA
Gamida Cell Ltd. Gamida Cell Ltd.
GMDA
-62.7 M - -18.25 % $ 5.04 M israelIsrael
Axcella Health Axcella Health
AXLA
-76.6 M - -16.42 % $ 249 M usaUSA
Metacrine Metacrine
MTCR
-60.8 M - - $ 24.2 M usaUSA
Zealand Pharma A/S Zealand Pharma A/S
ZEAL
-1.05 B - 0.52 % $ 821 M danmarkDanmark
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
-186 M - -0.04 % $ 2.62 B usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
-22.4 M - -74.18 % $ 955 K usaUSA
Idera Pharmaceuticals Idera Pharmaceuticals
IDRA
-27.7 M - -23.04 % $ 26.6 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-285 M - - $ 3.67 B usaUSA
Verona Pharma plc Verona Pharma plc
VRNA
-154 M - - $ 69.7 B britainBritain
Atreca Atreca
BCEL
5.46 M - -11.76 % $ 5.79 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
-4.32 M - -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
5.25 M - - $ 109 M usaUSA
Akouos Akouos
AKUS
-84.3 M - 0.23 % $ 488 M usaUSA
ImmunoGen ImmunoGen
IMGN
-219 M - - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
-14.4 M - -8.77 % $ 12.4 M israelIsrael
Cidara Therapeutics Cidara Therapeutics
CDTX
-176 M - - $ 1.41 B usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
-18.7 M - - $ 591 K irlandaIrlanda
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
-12.1 M - -45.12 % $ 2.85 M usaUSA
Navidea Biopharmaceuticals Navidea Biopharmaceuticals
NAVB
-14 M - -2.99 % $ 2.47 M usaUSA
Stealth BioTherapeutics Corp Stealth BioTherapeutics Corp
MITO
-46.2 M - - $ 23.9 M usaUSA
OncoSec Medical Incorporated OncoSec Medical Incorporated
ONCS
-36.8 M - 31.87 % $ 1.61 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
37.3 M - -4.8 % $ 255 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-123 M - -0.23 % $ 916 M usaUSA
bluebird bio bluebird bio
BLUE
-210 M - - $ 546 M usaUSA
Landos Biopharma Landos Biopharma
LABP
-22.7 M - 0.58 % $ 144 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
-32.8 M - - $ 35.4 M usaUSA
ContraFect Corporation ContraFect Corporation
CFRX
-64.5 M - -5.16 % $ 5.39 M usaUSA
Sigilon Therapeutics Sigilon Therapeutics
SGTX
-42.4 M - - $ 728 M usaUSA
Regulus Therapeutics Regulus Therapeutics
RGLS
-49.7 M - - $ 155 M usaUSA
NGM Biopharmaceuticals NGM Biopharmaceuticals
NGM
-149 M - - $ 127 M usaUSA
Aravive Aravive
ARAV
-70 M - -13.39 % $ 1.45 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-61.4 M - - $ 231 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
-513 M $ 84.95 0.13 % $ 7.99 B usaUSA
Acer Therapeutics Acer Therapeutics
ACER
-24.5 M - 2.71 % $ 14 M usaUSA
Gilead Sciences Gilead Sciences
GILD
10.4 B $ 166.01 -0.31 % $ 207 B usaUSA
Assembly Biosciences Assembly Biosciences
ASMB
-12 M $ 22.14 -1.6 % $ 248 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
505 K - - $ 2.02 B usaUSA
Turning Point Therapeutics Turning Point Therapeutics
TPTX
-237 M - -0.13 % $ 3.73 B usaUSA
Orgenesis Orgenesis
ORGS
-37.7 M - -33.86 % $ 61.2 M usaUSA
TCR2 Therapeutics TCR2 Therapeutics
TCRR
-150 M - - $ 58.1 M usaUSA